Comparing Cut Points Between Statistical Software Stata and R Using Random Effects Model

Comparing Cut Points Between Statistical Software Stata and R Using Random Effects Model
September 17, 2024 BioData Solutions

The high-stake and high-risk nature of drug discovery and development demands either the use of a validated system or sufficient proof to support the use of an open-source system. A validated system warrants that the system is fit-for-purpose, and that it accurately, consistently, and repeatedly performs per the requirements and specifications established prior to development. Open-source software is available to the public at no or minimal cost for use, inspection, and modification. While commercial software may be validated, open-source systems are economical and preferable for ad hoc tasks. However, open-source software may or may not have been thoroughly tested and validated. Learn more in this app note.

App Notes

Cross-Validation of Statistical Workflow for Cut Point Calculation using Red Thread (Python) Vs R

Cross-Validation of Statistical Workflow for Cut Point Calculation using Red Thread (Python) Vs R

Comparing Cut Points Between Statistical Software Stata and R Using Random Effects Model

Comparing Cut Points Between Statistical Software Stata and R Using Random Effects Model

Case Studies

Simplifying Bioanalytical Review Using Advanced Computational Techniques

Simplifying Bioanalytical Review Using Advanced Computational Techniques

Posters

Singlet Analysis Yields Equivalent Results as Duplicate Analysis in Preclinical Immunogenicity Assessment

Singlet Analysis Yields Equivalent Results as Duplicate Analysis in Preclinical Immunogenicity Assessment

Can Automation Improve Compliance, Consistency, & Efficiency for CGTP Data Analysis

Can Automation Improve Compliance, Consistency, & Efficiency for CGTP Data Analysis

White Papers

Artificial Intelligence increases efficiencies and reduces bias for bioanalytical pharmacokinetic studies and anti-drug antibody statistical determinations

Artificial Intelligence increases efficiencies and reduces bias for bioanalytical pharmacokinetic studies and anti-drug antibody statistical determinations